NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls

Neuroscience Letters

Volumn 594, Issue , 2015, Pages 36-39

  Öhman, Anders ^a   Forsgren, Lars ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Biomarker; Cerebrospinal fluid; Metabonomics; NMR; Parkinson's disease

Indexed keywords

3 HYDROXY 2 METHYLPROPIONIC ACID; 3 HYDROXYISOVALERIC ACID; ALANINE; BIOLOGICAL MARKER; CREATININE; DIMETHYLAMINE; GLUCOSE; HYDROXYACID; LACTIC ACID; MANNOSE; PHENYLALANINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSIS; FEMALE; HUMAN; MALE; METABOLOME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID; DIAGNOSIS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED; PARKINSON DISEASE;

EID: 84964199557     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.03.051     Document Type: Article

References (32)

1. Goedert M. Alpha-synuclein and neurodegenerative diseases, nature reviews. Neuroscience 2001, 2:492-501.
2. Lang A.E., Obeso J.A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 2004, 3:309-316.
3. Gibb W.R., Lees A.J. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988, 38:1402-1406.
4. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008, 455:1054-1056.
5. Quinones M.P., Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 2009, 35:165-176.
6. Smolinska A., Blanchet L., Buydens L.M., Wijmenga S.S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal. Chim. Acta 2012, 750:82-97.
7. Sinclair A.J., Viant M.R., Ball A.K., Burdon M.A., Walker E.A., Stewart P.M., Rauz S., Young S.P. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases - a diagnostic tool?. NMR Biomed. 2010, 23:123-132.
8. Ahmed S.S., Santosh W., Kumar S., Christlet H.T. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 2009, 16:63.
9. Bogdanov M., Matson W.R., Wang L., Matson T., Saunders-Pullman R., Bressman S.S., Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain: J. Neurol. 2008, 131:389-396.
10. Michell A.W., Mosedale D., Grainger D.J., Barker R.A. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics 2008, 4:191-201.
11. Jimenez-Jimenez F.J., Molina J.A., Vargas C., Gomez P., Navarro J.A., Benito-Leon J., Orti-Pareja M., Gasalla T., Cisneros E., Arenas J. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 1996, 141:39-44.
12. Johansen K.K., Wang L., Aasly J.O., White L.R., Matson W.R., Henchcliffe C., Beal M.F., Bogdanov M. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009, 4:e7551.
13. Lewitt P.A., Li J., Lu M., Beach T.G., Adler C.H., Guo L., Arizona C. Parkinson's disease, 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov. Disord. 2013, 28:1653-1660.
14. Mally J., Szalai G., Stone T.W. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 1997, 151:159-162.
15. Molina J.A., Jimenez-Jimenez F.J., Gomez P., Vargas C., Navarro J.A., Orti-Pareja M., Gasalla T., Benito-Leon J., Bermejo F., Arenas J. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol. Sci. 1997, 150:123-127.
16. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., Ascherio A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 2007, 166:561-567.
17. Garseth M., Sonnewald U., White L.R., Rod M., Zwart J.A., Nygaard O., Aasly J. Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea but not Parkinson disease. J. Neurosci. Res. 2000, 60:779-782.
18. Fathi F., Tafazzoli M., Mehrpour M., Shahidi G. Study of metabolic profiling Parkinson's disease. HealthMED 2013, 7:204-210.
19. Fathi F., Kyani A., Darvizeh F., Mehrpour M., Tafazzoli M., Shahidi G. Relationship between serum level of selenium and metabolites Using 1HNMR-based metabonomics in Parkinson's disease. Appl. Magn. Reson. 2013, 44:721-734.
20. Mandal R., Guo A.C., Chaudhary K.K., Liu P., Yallou F.S., Dong E., Aziat F., Wishart D.S. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med. 2012, 4:38.
21. Wishart D.S., Lewis M.J., Morrissey J.A., Flegel M.D., Jeroncic K., Xiong Y., Cheng D., Eisner R., Gautam B., Tzur D., Sawhney S., Bamforth F., Greiner R., Li L. The human cerebrospinal fluid metabolome. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 871:164-173.
22. Stoop M.P., Coulier L., Rosenling T., Shi S., Smolinska A.M., Buydens L., Ampt K., Stingl C., Dane A., Muilwijk B., Luitwieler R.L., Sillevis Smitt P.A., Hintzen R.Q., Bischoff R., Wijmenga S.S., Hankemeier T., van Gool A.J., Luider T.M. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol. Cell. Proteomics: MCP 2010, 9:2063-2075.
23. Aranibar N., Ott K.H., Roongta V., Mueller L. Metabolomic analysis using optimized NMR and statistical methods. Anal. Biochem. 2006, 355:62-70.
24. Bylesjö M., Rantalainen M., Cloarec O., Nicholson J., Holmes E., Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J. Chemom. 2006, 20:341-351.
25. Trygg J., Wold S. Orthogonal projections to latent structures (O-PLS). J. Chemom. 2002, 16:119-128.
26. ® models. J. Chemom. 2008, 22:594-600.
27. Wishart D.S., Jewison T., Guo A.C., Wilson M., Knox C., Liu Y., Djoumbou Y., Mandal R., Aziat F., Dong E., Bouatra S., Sinelnikov I., Arndt D., Xia J., Liu P., Yallou F., Bjorndahl T., Perez-Pineiro R., Eisner R., Allen F., Neveu V., Greiner R., Scalbert A. HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res. 2013, 41:D801-807.
28. Trupp M., Jonsson P., Ohrfelt A., Zetterberg H., Obudulu O., Malm L., Wuolikainen A., Linder J., Moritz T., Blennow K., Antti H., Forsgren L. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. J. Parkinson's Dis. 2014, 4:549-560.
29. Agren H., Niklasson F. Creatinine and creatine in CSF: indices of brain energy metabolism in depression. Short note. J. Neural Transm. 1988, 74:55-59.
30. Tsacopoulos M., Magistretti P.J. Metabolic coupling between glia and neurons. J. Neurosci. 1996, 16:877-885.
31. Sharma V., Ichikawa M., Freeze H.H. Mannose metabolism: More than meets the eye. Biochem. Biophys. Res. Commun. 2014, 453:220-228.
32. Reinke S.N., Broadhurst D.L., Sykes B.D., Baker G.B., Catz I., Warren K.G., Power C. Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Multiple Sclerosis 2014, 20:1396-1400.